Trial Profile
Retrospective study of alectinib in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who had not responded to crizotinib therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.